231 related articles for article (PubMed ID: 12482756)
41. Inverse solvent isotope effects arising from substrate triggering in the factor inhibiting hypoxia inducible factor.
Hangasky JA; Saban E; Knapp MJ
Biochemistry; 2013 Mar; 52(9):1594-602. PubMed ID: 23351038
[TBL] [Abstract][Full Text] [Related]
42. Factor-inhibiting hypoxia-inducible factor (FIH) catalyses the post-translational hydroxylation of histidinyl residues within ankyrin repeat domains.
Yang M; Chowdhury R; Ge W; Hamed RB; McDonough MA; Claridge TD; Kessler BM; Cockman ME; Ratcliffe PJ; Schofield CJ
FEBS J; 2011 Apr; 278(7):1086-97. PubMed ID: 21251231
[TBL] [Abstract][Full Text] [Related]
43. Crystal structures of human FIH-1 in complex with quinol family inhibitors.
Moon H; Han S; Park H; Choe J
Mol Cells; 2010 May; 29(5):471-4. PubMed ID: 20396966
[TBL] [Abstract][Full Text] [Related]
44. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.
Pastore Y; Jedlickova K; Guan Y; Liu E; Fahner J; Hasle H; Prchal JF; Prchal JT
Am J Hum Genet; 2003 Aug; 73(2):412-9. PubMed ID: 12844285
[TBL] [Abstract][Full Text] [Related]
45. From erythropoietin to oxygen: hypoxia-inducible factor hydroxylases and the hypoxia signal pathway.
Ratcliffe PJ
Blood Purif; 2002; 20(5):445-50. PubMed ID: 12207089
[TBL] [Abstract][Full Text] [Related]
46. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.
Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
EMBO J; 2003 Apr; 22(8):1857-67. PubMed ID: 12682018
[TBL] [Abstract][Full Text] [Related]
47. Proteomics-based identification of novel factor inhibiting hypoxia-inducible factor (FIH) substrates indicates widespread asparaginyl hydroxylation of ankyrin repeat domain-containing proteins.
Cockman ME; Webb JD; Kramer HB; Kessler BM; Ratcliffe PJ
Mol Cell Proteomics; 2009 Mar; 8(3):535-46. PubMed ID: 18936059
[TBL] [Abstract][Full Text] [Related]
48. Evidence that two enzyme-derived histidine ligands are sufficient for iron binding and catalysis by factor inhibiting HIF (FIH).
Hewitson KS; Holmes SL; Ehrismann D; Hardy AP; Chowdhury R; Schofield CJ; McDonough MA
J Biol Chem; 2008 Sep; 283(38):25971-8. PubMed ID: 18611856
[TBL] [Abstract][Full Text] [Related]
49. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
50. The zinc chelator, N,N,N',N'-tetrakis (2-pyridylmethyl) ethylenediamine, increases the level of nonfunctional HIF-1alpha protein in normoxic cells.
Choi SM; Choi KO; Lee N; Oh M; Park H
Biochem Biophys Res Commun; 2006 May; 343(4):1002-8. PubMed ID: 16579968
[TBL] [Abstract][Full Text] [Related]
51. Protein Flexibility of the α-Ketoglutarate-Dependent Oxygenase Factor-Inhibiting HIF-1: Implications for Substrate Binding, Catalysis, and Regulation.
Martin CB; Chaplin VD; Eyles SJ; Knapp MJ
Biochemistry; 2019 Oct; 58(39):4047-4057. PubMed ID: 31499004
[TBL] [Abstract][Full Text] [Related]
52. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch.
Lando D; Peet DJ; Whelan DA; Gorman JJ; Whitelaw ML
Science; 2002 Feb; 295(5556):858-61. PubMed ID: 11823643
[TBL] [Abstract][Full Text] [Related]
53. Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
Strowitzki MJ; Cummins EP; Taylor CT
Cells; 2019 Apr; 8(5):. PubMed ID: 31035491
[TBL] [Abstract][Full Text] [Related]
54. Signalling cross talk of the HIF system: involvement of the FIH protein.
Coleman ML; Ratcliffe PJ
Curr Pharm Des; 2009; 15(33):3904-7. PubMed ID: 19671041
[TBL] [Abstract][Full Text] [Related]
55. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor.
Ivan M; Haberberger T; Gervasi DC; Michelson KS; Günzler V; Kondo K; Yang H; Sorokina I; Conaway RC; Conaway JW; Kaelin WG
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13459-64. PubMed ID: 12351678
[TBL] [Abstract][Full Text] [Related]
56. Screening chelating inhibitors of HIF-prolyl hydroxylase domain 2 (PHD2) and factor inhibiting HIF (FIH).
Flagg SC; Martin CB; Taabazuing CY; Holmes BE; Knapp MJ
J Inorg Biochem; 2012 Aug; 113():25-30. PubMed ID: 22687491
[TBL] [Abstract][Full Text] [Related]
57. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
Kim W; Kaelin WG
Curr Opin Genet Dev; 2003 Feb; 13(1):55-60. PubMed ID: 12573436
[TBL] [Abstract][Full Text] [Related]
58. Proline hydroxylation at different sites in hypoxia-inducible factor 1α modulates its interactions with the von Hippel-Lindau tumor suppressor protein.
Qian H; Zou Y; Tang Y; Gong Y; Qian Z; Wei G; Zhang Q
Phys Chem Chem Phys; 2018 Jul; 20(27):18756-18765. PubMed ID: 29961792
[TBL] [Abstract][Full Text] [Related]
59. Activation of hypoxia-induced transcription in normoxia.
Hägg M; Wennström S
Exp Cell Res; 2005 May; 306(1):180-91. PubMed ID: 15878343
[TBL] [Abstract][Full Text] [Related]
60. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
